The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.

The purpose of this study is to characterize the natural history of DRPLA patients using a variety of clinical and biomarker modalities and to identify genetic factors, biomarkers, and clinical measures that could predict disease progression.

The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any other strokes, and follow their general recovery after stroke.

We are collecting cerebral spinal fluid (CSF) from Normal Pressure Hydrocephaly (NPH) patients to generate a biosample research repository. This repository will be used to research CSF biomarkers for Alzheimer's disease that may enhance our ability to detect and monitor Alzheimer's disease diagnoses and progression.

The purpose of this project is to create and distribute a survey with the intent to collect data about the amount and quality of training critical care physicians receive regarding brain death (i.e., death by neurologic criteria). We are doing because teaching physicians about brain death is not standardized and the subject is complex.

This study will evaluate the safety and effectiveness of a new intravenous (IV) medication (LT3001) for adult patients who have had a stroke. This new medication is designed to restore blood flow to the area of the brain affected, and reduce inflammation in the brain. Patients who agree to be in this study will receive 6 doses of the IV study drug while in the hospital. Patients will have extra labs drawn, head imaging studies and will be followed by the study team for 90 days after their hospital admission.

This study will gather information about patients who are taking new medicines for Alzheimer's disease. We'll keep an eye on how these patients are doing in the long run, tracking things like how they're responding to treatment, what their overall health outcomes are like, and how safe these new treatments really are when used in the real world. The goal of this study is to get a better understanding of how these therapies actually work for a diverse group of people, not just the people who usually participate in clinical trials.

The purpose of the study is to identify certain processes following brain injury that may be associated with the risk of developing epilepsy.

The purpose of the study is to provide a detailed view of the impact of MMN and MMN treatment on patients in the real world. This protocol aims to collect data from participants with MMN to characterize the disease's course and management and the humanistic and economic burden on patients

The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there is no investigational treatment involved. We will be working with patients for up to a 5 year period to learn more about FTLD using a neurological exam, tests of memory, behavior, and judgement, MRI, and biospecimen collection (blood and/or CSF). This study involves genetic testing of the genes so far identified to be associated with FTLD. The overall goal is to help better understand FTLD, to better understand the genetics of FTLD, and to use the information we learn to guide improved patient care and potential drug development.